ANEB Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q2

FY2026Q3

FY2026Q4

-0.130

+44.44%

-0.140

+250%

-0.100

+100%

Estimates Revision

The market is revising No Change the revenue expectations for Anebulo Pharmaceuticals, Inc. (ANEB) for FY2026, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -48.50%.

EPS Estimates for FY2026

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-48.50%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Anebulo Pharmaceuticals Inc (ANEB.O) is -2.35, compared to its 5-year average forward P/E of -7.70. For a more detailed relative valuation and DCF analysis to assess Anebulo Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-7.70

Current PE

-2.35

Overvalued PE

-0.27

Undervalued PE

-15.13

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ANEB News & Events

Events Timeline

No data

News

8.5

2025-12-22Benzinga

UniFirst Corp (UNF) Receives $5.2B Acquisition Proposal from Cintas (CTAS) at 64% Premium

4.5

2025-12-22Benzinga

U.S. Stocks Rise with Nasdaq Gaining Over 100 Points

2.0

2025-12-11NASDAQ.COM

Biotech Stocks Rise in After-Hours Trading Driven by Data Expectations and Momentum Buying

People Also Watch

Frequently Asked Questions

What is Anebulo Pharmaceuticals Inc (ANEB) stock price today?

The current price of ANEB is 1.2 USD — it has increased 0.84 % in the last trading day.

What is Anebulo Pharmaceuticals Inc (ANEB)'s business?

Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company. It is engaged in developing treatments for cannabis toxicity, such as unintentional cannabis poisoning, acute cannabinoid intoxication (ACI) and the landscape of acute cannabis-induced conditions. Its lead product candidate is selonabant, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabinoids, with the potential to address the unmet medical need for a therapy to treat cannabis toxicity. Selonabant is orally bioavailable, rapidly absorbed, and has also been formulated for intravenous administration. Selonabant is intended to rapidly reverse the negative effects of cannabis-induced toxicity and reduce time to recovery. It is also prioritizing the advancement of a selonabant intravenous (IV) formulation as a potential treatment for pediatric patients with cannabis-induced CNS depression.

What is the price predicton of ANEB Stock?

Wall Street analysts forecast ANEB stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANEB is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Anebulo Pharmaceuticals Inc (ANEB)'s revenue for the last quarter?

Anebulo Pharmaceuticals Inc revenue for the last quarter amounts to -2.26M USD, decreased -6.30 % YoY.

What is Anebulo Pharmaceuticals Inc (ANEB)'s earnings per share (EPS) for the last quarter?

Anebulo Pharmaceuticals Inc. EPS for the last quarter amounts to USD, decreased % YoY.

What changes have occurred in the market's expectations for Anebulo Pharmaceuticals Inc (ANEB)'s fundamentals?

How many employees does Anebulo Pharmaceuticals Inc (ANEB). have?

Anebulo Pharmaceuticals Inc (ANEB) has 2 emplpoyees as of January 09 2026.

What is Anebulo Pharmaceuticals Inc (ANEB) market cap?

Today ANEB has the market capitalization of 48.89M USD.